For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Stemcentrx, Inc.

USPTO Granted Patents = 18

% Expired Patents = 72.2

CIPO Patents = 4

Forward Citations = 138

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Scott J Dylla (18 out of 50 patents)

Orit Foord (17 out of 78 patents)

Robert A Stull (17 out of 44 patents)

4. Laura Saunders (14 out of 38 patents)

5. Michael Torgov (14 out of 49 patents)

6. Hui Shao (14 out of 36 patents)

7. David Y Liu (14 out of 108 patents)

8. Jeffrey Traer Bernstein (1 out of 183 patents)

9. Alexandra Leida Liana Lazetic (1 out of 10 patents)

10. Alex Bankovich (1 out of 5 patents)

11. Puja Sapra (1 out of 9 patents)

12. Johannes Hampl (1 out of 5 patents)

13. Wade C Anderson (1 out of 4 patents)

14. Saiyou Ohshima (1 out of 2 patents)

15. Kiran Khandke (1 out of 7 patents)

18 patents: Sort by Forward Citations

1. 9458231 - Modulators and methods of use (2016-10-04),

2. 9409995 - PTK7 modulators and methods of use (2016-08-09),

3. 9381205 - Anti-EFNA4 antibody-drug conjugates (2016-07-05),

4. 9358304 - Methods of making DLL3 antibody drug conjugates (2016-06-07),

5. 9353182 - Anti-DLL3 antibodies (2016-05-31),

6. 9352051 - Kits containing DLL3 antibody drug conjugates (2016-05-31),

7. 9345784 - Methods of delivering DLL3 antibody drug conjugates (2016-05-24),

8. 9334318 - Multivalent DLL3 antibodies (2016-05-10),

9. 9320812 - Modulators and methods of use (2016-04-26),

10. 9173959 - Anti-DLL3 antibody drug conjugates (2015-11-03),

11. 9155803 - Anti-DLL3 antibody drug conjugates and methods of use (2015-10-13),

12. 9133271 - Anti-DLL3 antibody drug conjugates and methods of use (2015-09-15),

13. 9107961 - Anti-DLL3 antibody drug conjugates for treating cancer (2015-08-18),

14. 9090683 - Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies (2015-07-28),

15. 9089617 - Anti-DLL3 antibody drug conjugates (2015-07-28),

Stemcentrx, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer patients. The company's mission is to enhance patients' lives by creating targeted treatments that address the underlying mechanisms of cancer. Stemcentrx utilizes cutting-edge technology and a deep understanding of cancer biology to discover and develop potential breakthrough drugs. Through its research and development efforts, Stemcentrx aims to revolutionize cancer treatment and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

18 Patents

#73 in South San Francisco, CA

#4,271 in California

#17,912 in US

#34,095 in the World

South San Francisco, CA, United States of America

Stemcentrx, Inc.

Forward Citations = 138

17 inventors:

Scott J Dylla (18 out of 50 patents)

Orit Foord (17 out of 78 patents)

Robert A Stull (17 out of 44 patents)

4. Laura Saunders (14 out of 38 patents)

5. Michael Torgov (14 out of 49 patents)

Please report any incorrect information to [email protected]

Loading…